欧林生物(688319) - 2024 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of RMB 588.86 million, a year-on-year increase of 18.69%[4] - Operating profit reached RMB 21.31 million, reflecting a significant growth of 587.68% compared to the previous year[4] - Total profit amounted to RMB 22.30 million, representing a year-on-year increase of 42.80%[4] - Net profit attributable to the parent company was RMB 19.58 million, up 11.50% from the previous year[4] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was RMB 10.00 million, a remarkable increase of 195.11%[4] - Basic earnings per share were RMB 0.0483, an increase of 11.55% compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 1,807.04 million, a growth of 12.06% from the beginning of the period[4] - Equity attributable to the parent company was RMB 923.50 million, showing a slight increase of 0.72%[4] Market Performance - The company strengthened market promotion, leading to stable growth in the sales of tetanus vaccines[6] Earnings Announcement - The company reported no significant uncertainties affecting the accuracy of the earnings announcement[8]